AlloVir Management

Management criteria checks 3/4

AlloVir's CEO is Diana Brainard, appointed in May 2021, has a tenure of 3.83 years. total yearly compensation is $6.06M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $216.91K. The average tenure of the management team and the board of directors is 4.8 years and 3.8 years respectively.

Key information

Diana Brainard

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage	10.3%
CEO tenure	3yrs
CEO ownership	0.2%
Management average tenure	4.8yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

CEO Compensation Analysis

How has Diana Brainard's remuneration changed compared to AlloVir's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$6m	US$623k	-US$190m
Sep 30 2023	n/a	n/a	-US$169m
Jun 30 2023	n/a	n/a	-US$167m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$9m	US$605k	-US$169m
Sep 30 2022	n/a	n/a	-US$189m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$185m
Dec 31 2021	US$15m	US$365k	-US$172m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$117m
Mar 31 2021	n/a	n/a	-US$91m
Dec 31 2020	US$597k	n/a	-US$70m

Compensation vs Market: Diana's total compensation ($USD6.06M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Diana's compensation has been consistent with company performance over the past year.

CEO

Diana Brainard (51 yo)

3yrs

Tenure

US$6,056,943

Compensation

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Hallal	Executive Chairman of the Board	5.7yrs	US$347.00k	2.45% $ 2.2m
Diana Brainard	CEO & Director	3yrs	US$6.06m	0.24% $ 216.9k
Vikas Sinha	President	5.3yrs	US$2.94m	0.81% $ 721.7k
Edward Miller	General Counsel & Secretary	5.3yrs	US$1.89m	0.37% $ 328.7k
Brett Hagen	Chief Accounting Officer	5.3yrs	no data	0.070% $ 61.7k
Dana Alexander	Senior Vice President of Technical Operations	4.3yrs	no data	no data
Ann Leen	Chief Scientific Officer	11.3yrs	no data	2.07% $ 1.8m
Cintia Piccina	Chief Commercial Officer	less than a year	no data	no data

4.8yrs

Average Tenure

50.5yo

Average Age

Experienced Management: ALVR's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Hallal	Executive Chairman of the Board	5.7yrs	US$347.00k	2.45% $ 2.2m
Diana Brainard	CEO & Director	3.8yrs	US$6.06m	0.24% $ 216.9k
Vikas Sinha	President	5.3yrs	US$2.94m	0.81% $ 721.7k
John Mellors	Member of the Scientific Advisory Board	1.3yrs	no data	no data
Malcolm Brenner	Independent Non-Executive Director	12.3yrs	US$196.28k	0.18% $ 157.9k
Jeffrey Bornstein	Independent Non-Executive Director	3.8yrs	US$211.78k	0.036% $ 31.9k
Michael Boeckh	Member of Scientific Advisory Board	1.3yrs	no data	no data
John DiPersio	Member of Scientific Advisory Board	1.3yrs	no data	no data
Anil Chandraker	Member of Scientific Advisory Board	1.3yrs	no data	no data
Morana Jovan-Embiricos	Independent Non-Executive Director	5yrs	US$209.28k	8.83% $ 7.8m
Shawn Tomasello	Independent Director	2.2yrs	US$200.73k	0% $ 0
Juan Vera	Non-Executive Director	10.3yrs	US$187.00k	2.1% $ 1.9m

3.8yrs

Average Tenure

57yo

Average Age

Experienced Board: ALVR's board of directors are considered experienced (3.8 years average tenure).

AlloVir Management

Management criteria checks 3/4

Key information

Recent management updates

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

High number of new directors

CEO & Director notifies of intention to sell stock

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

Recent updates

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 3000E Value Index

Chief Scientific Officer recently sold US$3.4m worth of stock

AlloVir EPS misses by $0.08

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Independent Non-Executive Director notifies of intention to sell stock

New 90-day low: US$34.53